PR Newswire All News ReleasesQwen · 实盘不做把握 9/10不做原因:标的无直接敞口
北京时间·🕒 发布 18:30:00·⟳ 抓取 18:30:16 +16s·⚡ 决策 09-01 18:32:31 +2m15s·56.0 天前
美敦力战略投资以色列Pi-Cardia，获ShortCut™瓣叶修饰技术独家经销权及最高2.1亿美元收购期权
美敦力市值约1500亿美元，8000万美元投资+2.1亿收购期权合计不足市值0.2%，属超大市值软催化，无可辨识短线价格增量。Pi-Cardia为私有公司不可交易。A股/港股结构心脏公司（佰仁医疗、启明医疗、沛嘉医疗等）是美敦力TAVR竞争对手，美敦力强化自身组合对其无正向因果敞口。无任何可交易标的具备足够materiality和因果链。
📄 原文PR Newswire All News Releases↗ 原文
Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR
GALWAY, Ireland and REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in health…
不做 美敦力（MDT.US）
超大市值（~$150B）软催化：$80M投资仅占市值~0.05%，$210M收购期权占~0.14%，无可辨识短线价格增量。属典型megacap软催化，不满足事件相对市值的增量门槛。
不做 Pi-Cardia Ltd.（N/A）
私有公司，无公开可交易证券。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
美敦力（市值~$150B）向私有公司Pi-Cardia投资最高$80M并获$210M收购期权，投资额仅占市值0.05-0.14%，对超大市值公司无可辨识短线催化。Pi-Cardia未上市，无公开交易载体。ShortCut为Pi-Cardia专有技术，不产生行业级需求外溢；美敦力借此强化TAVR竞争力，对A股/港股国产瓣膜企业（佰仁、启明、沛嘉）为竞争加剧而非利好。综合判断无任何可交易标的具备正向因果敞口和足够materiality。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:因事件对可交易标的无足够materiality，先例研究不改变AVOID结论
方向:不适用
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 2 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 597 ms
{"result": "search_processed_events:agent query=`medtronic pi-cardia strategic investment | medtronic shortcut leaflet modification tavr | 美敦力 pi-cardia 投资 结构心脏`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.6/72 小时、1972 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 降级 stock_tools HTTP · 1,677 ms
取价失败: Futu returned no quote - get_stock_profile 成功 stock_tools HTTP · 5,514 ms
{"result": "查询「TAVR」成分股失败: (2003, \"Can't connect to MySQL server on '192.168.31.176' (timed out)\")"}
原文全文
展开原文 · 4,730 字
GALWAY, Ireland and REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and Pi-Cardia Ltd., a pioneer in leaflet modification technologies for structural heart disease, today announced a strategic investment by Medtronic in Pi-Cardia Ltd. With a focus on addressing the evolving needs of increasingly complex transcatheter aortic valve replacement (TAVR) patients and procedures, Medtronic secures an option for strengthening its structural heart portfolio through this strategic investment, supporting the next generation of innovation.
Pi-Cardia's ShortCut™ device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction. The device provides physicians with a safe, easy-to-learn, reproducible approach to leaflet modification that can help preserve coronary access and enable future transcatheter valve procedures. In FDA-reviewed clinical studies, ShortCut™ demonstrated successful leaflet splitting in all pivotal trial patients and a favorable safety profile.
"As structural heart care evolves, we're investing in technologies that help physicians address today's challenges while preparing for tomorrow's opportunities," said Jorie Soskin, vice president and general manager of the Structural Heart business within Medtronic's Cardiovascular portfolio. "Our investment in Pi-Cardia reflects our commitment to building a portfolio of technologies that will shape the future of TAVR, particularly for patients with complex anatomy. We believe leaflet modification technologies like ShortCut have the potential to become an important component of structural heart care and the future of TAVR as transcatheter therapies continue to advance."
Under the agreement, Medtronic will make strategic investments of up to $80 million into Pi-Cardia and is expected to become the exclusive global commercial distributor of the ShortCut device in 2027. Medtronic will leverage its worldwide Structural Heart organization to expand physician access across the United States, Europe, Japan and other international markets. The agreement also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, subject to customary adjustments, plus additional potential earn-out payments post-acquisition that could meaningfully increase the total consideration. The transactions are subject to regulatory approval and customary closing conditions.
"Our mission has been to make leaflet modification a standard part of complex TAVR," said Erez Golan, Chief Executive Officer of Pi-Cardia. "Medtronic is the right partner to help us achieve this vision given their global reach and commitment to bringing innovative tools to physicians and patients worldwide. We are confident this collaboration will accelerate adoption of ShortCut while continuing to advance the future of leaflet modification."
The strategic investment secures an option for Medtronic to strengthen its structural heart portfolio by adding a first-of-its-kind technology that addresses a significant challenge in valve-in-valve TAVR while complementing the company's leadership in transcatheter valve therapies. It also reflects Medtronic's commitment to partnering and investing early in innovations that can improve patient outcomes, expand future treatment options, and support long-term growth.
Pi-Cardia was founded by Erez Golan and Eyal Kolka, and is backed by experienced medtech investors including Sofinnova Partners, Sprig Equity, and Jacques Séguin, whose commitment has helped advance the company's vision of developing transformative leaflet modification technologies.
About Pi-Cardia
Pi-Cardia Ltd. is a privately held medical device company dedicated to developing innovative structural heart technologies that address unmet clinical needs. Its proprietary leaflet modification platform is designed to improve procedural outcomes and expand treatment options for patients undergoing transcatheter valve interventions.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission, to alleviate pain, restore health, and extend life, unites a global team of employees dedicated to transforming healthcare and improving lives around the world.
Contacts:
Kimberly Powell
Public Relations
+1-202-498-2601
Ingrid Goldberg
Investor Relations
+1-763-505-2696
SOURCE Medtronic plc
Pi-Cardia's ShortCut™ device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction. The device provides physicians with a safe, easy-to-learn, reproducible approach to leaflet modification that can help preserve coronary access and enable future transcatheter valve procedures. In FDA-reviewed clinical studies, ShortCut™ demonstrated successful leaflet splitting in all pivotal trial patients and a favorable safety profile.
"As structural heart care evolves, we're investing in technologies that help physicians address today's challenges while preparing for tomorrow's opportunities," said Jorie Soskin, vice president and general manager of the Structural Heart business within Medtronic's Cardiovascular portfolio. "Our investment in Pi-Cardia reflects our commitment to building a portfolio of technologies that will shape the future of TAVR, particularly for patients with complex anatomy. We believe leaflet modification technologies like ShortCut have the potential to become an important component of structural heart care and the future of TAVR as transcatheter therapies continue to advance."
Under the agreement, Medtronic will make strategic investments of up to $80 million into Pi-Cardia and is expected to become the exclusive global commercial distributor of the ShortCut device in 2027. Medtronic will leverage its worldwide Structural Heart organization to expand physician access across the United States, Europe, Japan and other international markets. The agreement also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, subject to customary adjustments, plus additional potential earn-out payments post-acquisition that could meaningfully increase the total consideration. The transactions are subject to regulatory approval and customary closing conditions.
"Our mission has been to make leaflet modification a standard part of complex TAVR," said Erez Golan, Chief Executive Officer of Pi-Cardia. "Medtronic is the right partner to help us achieve this vision given their global reach and commitment to bringing innovative tools to physicians and patients worldwide. We are confident this collaboration will accelerate adoption of ShortCut while continuing to advance the future of leaflet modification."
The strategic investment secures an option for Medtronic to strengthen its structural heart portfolio by adding a first-of-its-kind technology that addresses a significant challenge in valve-in-valve TAVR while complementing the company's leadership in transcatheter valve therapies. It also reflects Medtronic's commitment to partnering and investing early in innovations that can improve patient outcomes, expand future treatment options, and support long-term growth.
Pi-Cardia was founded by Erez Golan and Eyal Kolka, and is backed by experienced medtech investors including Sofinnova Partners, Sprig Equity, and Jacques Séguin, whose commitment has helped advance the company's vision of developing transformative leaflet modification technologies.
About Pi-Cardia
Pi-Cardia Ltd. is a privately held medical device company dedicated to developing innovative structural heart technologies that address unmet clinical needs. Its proprietary leaflet modification platform is designed to improve procedural outcomes and expand treatment options for patients undergoing transcatheter valve interventions.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission, to alleviate pain, restore health, and extend life, unites a global team of employees dedicated to transforming healthcare and improving lives around the world.
Contacts:
Kimberly Powell
Public Relations
+1-202-498-2601
Ingrid Goldberg
Investor Relations
+1-763-505-2696
SOURCE Medtronic plc
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。